FTC settles with AbbVie, ending Actavis

The Federal Trade Commission wrapped up a watershed pay-for-delay lawsuit on Thursday, settling its claims that AbbVie had illegally paid off generic rivals to keep them from competing in a market for testosterone medication.

Get unlimited access to all Global Competition Review content